A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE）

Angde Biotech Pharmaceutical

Status and phase: Completed; Phase 3

Conditions: Acute Ischemic Stroke

Treatments: Drug: Recombinant human tissue plasminogen activator; Drug: Injection of recombinant human tissue plasminogen kinase derivatives

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT05295173

CRAD-001-03

Details and patient eligibility

About

The purpose of this study is to assess the efficacy and safety of recombinant human tissue plasminogen kinase derivatives for injection and alteplase in the treatment of patients with acute ischemic stroke within 4.5 hours.

Full description

This study is a multicenter, randomized, blind endpoint and positive drug control study.

The study plans to recruit 1412 AIS patients within 4.5 hours of onset. Qualified subjects are assigned to the test drug and control drug alteplase group according to the ratio of 1:1. After receiving thrombolytic drugs, the subjects need to carry out a series of safety and effectiveness tests. The mRS score and Barthel index score visits are carried out on the 90th day (± 7 days) after thrombolysis. After the visit, the subjects can leave the group.

In this study, independent blind endpoint evaluators were set up in each research center to evaluate the mRS and Barthel index score 30 and 90 days after thrombolysis.

Enrollment: 1,412 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Aged 18 to 80 years（including the critical value);
2. Acute ischemic stroke is diagnosed according to the WHO (World Health Organization) stroke diagnostic criteria, the symptoms of acute ischemic stroke are expected to be less than 4.5 hours after the time of acute ischemic stroke which is defined as the last time the patient functions well;
3. NIHSS score at the time of treatment: from 4 points to 25 points (including 4 points and 25 points);
4. From the signing of informed consent form to 3 months after treatment, fertile men and women of childbearing age should be absent of a birth plan and willing to take effective contraceptive measures;
5. Participants who can understand and follow the research process, voluntarily participate, and sign an informed consent form (informed consent is voluntarily signed by the person or legal representative).

Exclusion criteria

1. Known to be allergic to research drugs or similar ingredients, or materials used in imaging studies;
2. Weight >120kg or <45kg;
3. The timing of stroke symptoms is not known;
4. mRS score before stroke≥ 2 points;
5. NIHSS score 1a (level of consciousness) ≥ 2 points during screening;
6. Patients with intracerebral hemorrhage history;
7. CT/MRI imaging examination shows signs of intracranial hemorrhage or suspected subarachnoid hemorrhage despite CT/MRI imaging findings do not show abnormalities;
8. Severe cerebral trauma or stroke history or other severe traumas within 3 months;
9. Assessment of Intracranial tumor, arteriovenous malformation and aneurysm before admission;
10. Intracranial surgery, intraspinal surgery or other major surgeries within 3 months (based on the assessment of the investigators);
11. Patients with gastrointestinal or urinary system hemorrhage in recent 3 weeks;
12. Active visceral hemorrhage;
13. Assessment or with history of aortic arch dissection before admission;
14. Arterial puncture in 1 week which can not be oppressed;
15. Subjects who have an acute bleeding tendency, including but not limited to：1) a platelet count of less than 100 × 109 / L；2) application of low molecular heparin within 24 hours before onset ; 3) Using of thrombin inhibitors or factor Xa inhibitor within 48 hours before onset ; 4) application of oral anticoagulant drugs and with an INR > 1.7 or PT>15s;
16. Hypertension remains uncontrolled after active antihypertensive therapy, uncontrolled hypertension refers to a systolic blood pressure >185 mmHg and/or a diastolic blood pressure >110 mmHg;
17. Blood glucose <50 mg/dl (equivalent to 2.78mmol/L) or >400 mg/dl (equivalent to 22.2mmol/L);
18. Imaging (CT or MRI)shows large area cerebral infarction;
19. Severe liver damage, including liver failure, cirrhosis, portal hypertension (esophageal varices), and active hepatitis;
20. Bacterial endocarditis or pericarditis, acute pancreatitis at admission;
21. With history of gastrointestinal ulcers, esophageal varices, aneurysms, or arterial / venous malformations within 3 months before admission;
22. Patients who are unable to cooperate or are unwilling to cooperate with epileptic seizures, or other mental illnesses during stroke episodes;
23. Patients who are ready to go or have undergone endovascular treatment;
24. The restricted drug specified in the protocol or any drug that may interfere with the test results must be ingested or desired to continue to be ingested;
25. An expected survival time of no more than 1 year due to other diseases;
26. Patients who are participating in other trials or have participated in other trials within 30 days before randomization;
27. Pregnancy or lactation, or women who have a positive pregnancy test result;
28. The subject who is unsuitable for this study in the opinion of the investigators.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

1,412 participants in 2 patient groups

experimental group

Experimental group

Description:

Recombinant human tissue plasminogen kinase derivatives(r-PA) for injection: the first intravenous bolus injection of 18mg, after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time. Subjects were closely monitored during the treatment period and within 24 hours after administration.

Treatment:

Drug: Injection of recombinant human tissue plasminogen kinase derivatives

comparative group

Active Comparator group

Description:

Recombinant human tissue plasminogen activator (rt-PA) for injection: 0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h. Subjects should be closely monitored during the treatment period and within 24 hours after administration.

Treatment:

Drug: Recombinant human tissue plasminogen activator